Large-scale (Phase III) evaluation of broflanilide 50WP (VECTRON™ T500) for indoor residual spraying for malaria vector control in Northeast Tanzania: study protocol for a two-arm, non-inferiority, cluster-randomised community trial.
Patrick K TunguMark W RowlandLouisa A MessengerGraham J SmallJohn BradleyJanneke SnetselaarMatthew J KirbyNjelembo J MbewePublished in: BMC infectious diseases (2022)
ClinicalTrials.gov, NCT05150808, registered on 26 November 2021. Retrospectively registered.